Expert Opin Pharmacother. 2010 Dec;11(17):2775-8. doi: 10.1517/14656566.2010.517196.
Management of persistent AF involves rhythm or rate control strategies and thromboprophylaxis for cardioembolic events. Although amiodarone appears to be more effective than other current antiarrhythmics for a rhythm control approach in AF patients, many side effects limit its long-term use. Dronedarone is a new antiarrhythmic drug that may offer advantages for rhythm control, given its relative safety (although not in patients with decompensated heart failure), efficacy and tolerability. With regard to the latter, dronedarone has fewer adverse effects and is better tolerated than amiodarone. Nonetheless, in one head-to-head comparison of dronedarone and amiodarone, the latter drug was superior to dronedarone for maintenance of sinus rhythm post cardioversion, but dronedarone was safer and better tolerated, with useful benefit to decrease hospitalizations and thus healthcare costs. This provides clinicians (and patients) with a new option when choosing antiarrhythmic therapy.
持续性房颤的管理包括节律或心率控制策略以及预防心源性栓塞事件的血栓预防。虽然胺碘酮在房颤患者的节律控制方法中似乎比其他当前的抗心律失常药物更有效，但许多副作用限制了其长期使用。多非利特是一种新型抗心律失常药物，因其相对安全性（尽管在心力衰竭失代偿患者中并非如此）、疗效和耐受性，可能在节律控制方面具有优势。关于后者，多非利特的不良反应比胺碘酮少，耐受性更好。尽管如此，在多非利特和胺碘酮的头对头比较中，后者在电复律后维持窦性节律方面优于多非利特，但多非利特更安全且耐受性更好，可减少住院次数，从而降低医疗保健成本，这为临床医生（和患者）在选择抗心律失常治疗时提供了一个新的选择。
